Skip to main content
DYN logo

DYN · Dyne Therapeutics, Inc.

Track DYN — free
$15.50 -0.53 (-3.31%) At close · Nov 20
Market Cap
$2.90B
Shares
187.39M
Volume · Nov 20 2.23M Avg daily vol (3M) 2.91M

Price & Indicators

 

Key stats

Close
$15.50
Fri 20 Nov
Open
$15.91
Fri 20 Nov
Average volume, 30 days
2.5M
shares a session
Short interest
24.4M
13.0% of shares · 10.8 days to cover
Day range
$15.41$16.48
Open $15.91 Close $15.50
52-week closing range
$14.25$26.78
Close $15.50 42.1% under the high
Short volume, last session
33%
Last earnings
Sep 3, 2024
Latest filing
10-Q · Nov 5
Price history
Sep 2020 to Nov 2026

Latest documents

2026
Nov 16
Investor event
Q1 DM1 data and DMD U.S. launch targeted

Dyne Therapeutics expects Q1 registrational data from a 71-patient DM1 expansion cohort and plans a Q1 U.S. launch for DMD. Its Phase III confirmatory trial will enroll 150 patients randomized one-to-one.

4 source passages
We have 71 patients in this registrational expansion cohort, and we believe we will be stat sig on VHOT. Registrational endpoint data that we expect to turn over in Q1 of this year as well, this coming year. We're saying it'll be in Q1. We are running a Phase III confirmatory trial called Harmonia, which has 150 patients randomized one-to-one. Open the document at this passage
Nov 5
Current report 8-K
FDA action date set; quarterly net loss widened

Dyne Therapeutics, Inc. reported a $193.6 million quarterly net loss and $1.134 billion in cash, cash equivalents and marketable securities, with funding expected into the second quarter of 2028; z-rostudirsen’s FDA PDUFA target action date is January 21, 2027.

Financial results
4 source passages
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today reported financial results for the third quarter of 2026 and recent business highlights. Dyne’s BLA is under priority review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of January 21, 2027. Cash, cash equivalents and marketable securities were $1.134 billion as of September 30, 2026. The Company expects that its cash, cash equivalents and marketable securities as of September 30, 2026, will be sufficient to fund its operations into the second quarter of 2028. Net loss: Net loss for the three months ended September 30, 2026 was $193.6 million, or $1.06 per basic and diluted share. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
FDA Reviews z-rostudirsen With January 21, 2027 Action Date

Dyne Therapeutics’ FDA accepted the BLA for z-rostudirsen in DMD, with priority review and a PDUFA target date of January 21, 2027; potential U.S. launch is expected in the first quarter of 2027.

Net loss $193.55M Diluted EPS -$1.06
Read from the MD&A section
3 source passages
In July 2026, we announced that the FDA accepted for review our BLA for z-rostudirsen for the treatment of individuals with DMD amenable to exon 51 skipping. The FDA has granted the BLA priority review and assigned a Prescription Drug User Fee Act, or PDUFA, target action date of January 21, 2027. We continue to expect a potential U.S. launch of z-rostudirsen in the first quarter of 2027, assuming FDA approval is received on the anticipated timeline. Open the document at this passage
Sep 29
Current report 8-K
Regulation FD disclosure, Other events

Dyne Therapeutics announced additional ACHIEVE trial data showing z-basivarsen improved myotonia, function, strength and patient-reported outcomes in a pooled dose group, with no related serious adverse events reported; ACHIEVE registrational expansion cohort topline data are planned for Q1 2027.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$604.92M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-19.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$713.19M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+31.2%
Year over year · more shares
Price change (1Y)
-23.0%
Trailing year
Short interest
13.0%
Latest settlement · 10.8 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Weak Sentiment Very Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −20%
below
Price vs 50-day avg −6%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 10%
near low
Momentum
relative strength
Weak
1-month return −1%
trailing
6-month return −10%
trailing
YTD return −21%
this year
Relative strength −1%
vs S&P · 6-mo
Sentiment
smart money
Very Bullish
Trend (MA cross) No cross
50d $17 › 200d $19 — 200d above 50d
Institutional flow Accumulating
+11% holders QoQ · +62 funds added
Insider flow Accumulating
Net +$40.0K over 90 days · 0% sells
Short interest Falling
13.01% of shares out · ▼ -4.3% MoM · 10.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
274 holders — near 3-yr high, broad support
Squeeze score 68
elevated · 0–100
Fundamentals
Weak
EPS growth −3%
Y/Y
Free cash flow $-405.1M
Balance sheet $744.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 64%
annualized · 1-yr
Max drawdown −47%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−20% Bearish
Price vs 50-day avg
−6% Bearish
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
10% Bearish
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) No cross
50d $17 › 200d $19 — 200d above 50d
Institutional flow Accumulating
+11% holders QoQ · +62 funds added
Insider flow Accumulating
Net +$40.0K over 90 days · 0% sells
Short interest Falling
13.01% of shares out · ▼ -4.3% MoM · 10.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
274 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $14 Now $16 · 10% Range high $27
vs 200-day avg -20% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
general and administrative headcount 44 the three months ended June 30, 2026 filing —
Participants enrolled in registrational expansion cohort (ACHIEVE) 71 June 2026 —
research and development headcount 39 the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DYN
Dyne Therapeutics, Inc.
this stock
$2.90B -20.8% — — 13.0%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
274
% held
114.0%
Net QoQ
+23.0M sh
Top holder
T. Rowe Price Investment…
Held Float
View
Held by Funds
Fund positions
250
View
Short & Settlement
Short Interest Falling
Shares short
24.4M
Days to cover
10.8d
Change
-1.1M sh
View
Short Volume
Short vol %
33%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
506
Value
$8.6K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
43.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$40.0K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-446.2M
EPS diluted
$-3.47
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 16, 2026
This year
25

Dyne Therapeutics expects Q1 registrational data from a 71-patient DM1 expansion cohort and plans a Q1 U.S. launch for DMD. Its Phase III confirmatory trial will enroll 150 patients randomized one-to-one.

View
Proposed Sales
Value
$43.8K
Shares
2.6K
Filed
Nov 13, 2026
View
Exempt Offerings
Offering
$115.7M
Filed
Aug 14, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 16, 2026
View
Investor Relations
Latest news
Dyne Therapeutics to Participate…
Published
Nov 11, 2026
View

Performance

5D 20D 120D MTD YTD
DYN -9.7% -0.8% -10.1% -7.1% -20.8%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -1.1% +8.5% -0.9% +1.6% -21.9%
Key facts CIK 1818794 CUSIP 26818M108 13F (30d) 281 filings 255 filers Visit website Investor relations